Patents Assigned to UCL BUSINESS LTD
  • Patent number: 10925943
    Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 23, 2021
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Brian Philip
  • Publication number: 20210002648
    Abstract: The present invention relates to analgesic treatments to reduce pain through use of an inhibitor of fatty-acid amide hydrolase pseudogene (FAAH-OUT).
    Type: Application
    Filed: February 12, 2019
    Publication date: January 7, 2021
    Applicant: UCL BUSINESS LTD
    Inventors: James John Cox, Devjit Srivastava
  • Patent number: 10881613
    Abstract: The present invention relates to fumarate polymersomes. The polymersomes are capable of targeting immune cells and then hydrolysing to release the immunomodulatory compound fumarate. The polymersomes can thus be used methods for the treatment of prevention of diseases, including immune diseases such as multiple sclerosis and psoriasis.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: January 5, 2021
    Assignee: UCL BUSINESS LTD
    Inventor: Giuseppe Battaglia
  • Patent number: 10874611
    Abstract: The present invention relates to polymersomes that contain an encapsulated drug and that exhibit chemotaxis in response to a chemical stimulus. The chemotactic polymersomes can be targeted in vivo to a location of therapeutic interest with high specificity and selectivity. The present invention also provides related pharmaceutical compositions and therapeutic methods.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 29, 2020
    Assignee: UCL BUSINESS LTD
    Inventor: Giuseppe Battaglia
  • Patent number: 10864163
    Abstract: The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 15, 2020
    Assignee: UCL Business LTD
    Inventor: Richard Michael Day
  • Patent number: 10842885
    Abstract: The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion of the coding sequence is not wild type. The present invention further relates to viral particles comprising a recombinant genome comprising the polynucleotide of the invention, compositions comprising the polynucleotides or viral particles, and methods and uses of the polynucleotides, viral particles or compositions.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: November 24, 2020
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Jenny McIntosh
  • Patent number: 10828263
    Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: November 10, 2020
    Assignee: UCL Business Ltd
    Inventors: Mohan Edirisinghe, Ming Wei Chang, Eleanor Stride
  • Publication number: 20200330591
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.
    Type: Application
    Filed: December 27, 2019
    Publication date: October 22, 2020
    Applicant: UCL Business Ltd
    Inventors: Vineeta TRIPATHI, Rose SHERIDAN, John GREENWOOD, Stephen MOSS
  • Patent number: 10792395
    Abstract: This invention relates to a method of producing a decellularised tissue scaffold which comprising treating a sample of tissue with an osmotic reagent and a detergent whilst subjecting the tissue sample to oscillation with a displacement of 1 mm or more and a frequency of 3 Hz or more during these treatment steps. This method may be useful in producing acellular scaffolds that maintain the 3-D architecture and extracellular matrix composition and morphology of the native tissue.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: October 6, 2020
    Assignee: UCL Business Ltd
    Inventors: Giuseppe Mazza, Walid Al-Akkad Abu Zeina, Massimo Pinzani
  • Patent number: 10792336
    Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a Factor VIII protein, wherein a B domain portion of the Factor VIII protein is encoded by a nucleotide sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a Factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: October 6, 2020
    Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, UCL BUSINESS LTD
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • Patent number: 10781162
    Abstract: The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 22, 2020
    Assignee: UCL Business Ltd
    Inventors: Alex Peter Dyson, Daniel Gooding, Joanne Holland
  • Patent number: 10780059
    Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 22, 2020
    Assignee: UCL Business Ltd
    Inventors: Mohan Edirisinghe, Ming Wei Chang, Eleanor Stride
  • Patent number: 10752665
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL) which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 25, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • Patent number: 10745715
    Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
  • Patent number: 10730942
    Abstract: The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 4, 2020
    Assignee: UCL Business Ltd
    Inventors: Martin Pule, Paul Maciocia, Ben Grimshaw
  • Patent number: 10734778
    Abstract: Apparatus and method establish quantum oscillations at room temperature. A cavity has therein a resonator structure that includes a resonant element and a gain medium. A species of the gain medium has an electronic spin multiplicity capable of supporting a two-level spin system. An optical pump pumps the resonator structure and thereby generates microwave output power through stimulated emission of thermal photons. The species of the gain medium is of a sufficiently high concentration such as to have an ensemble spin-photon coupling rate which exceeds both the cavity mode decay rate and the spin-spin decoherence rate. The optical pump pumps the resonator structure using a short pulse of nanosecond duration, or a burst of approximately a millisecond in duration at relatively low instantaneous optical power, to excite said species of the gain medium into a spin-polarized two-level system that exhibits quantum oscillations in the microwave output power.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: August 4, 2020
    Assignees: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, UCL BUSINESS LTD
    Inventors: Jonathan David Baxendale Breeze, Enrico Salvadori, Chris Kay
  • Patent number: 10704032
    Abstract: The present invention relates to a retrovirus packaging cell which expresses a temperature sensitive RNA-dependent-RNA polymerase (RdRp).
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
  • Publication number: 20200163326
    Abstract: Methods and materials for the cryopreservation of cellularised scaffolds used for therapeutic or pharmacological testing purposes that provide a cultured scaffold on which cells have been seeded, equilibrate the cellularised scaffold with a cryopreservative composition comprising culture medium and between 5 and 30% of a cryoprotectant such as DMSO, freeze the equilibrated cellularised scaffold by reducing the temperature continuously by about ?1° C./minute to about ?80° C., and store the frozen cellularised scaffold at a temperature of between ?135° C. and ?198° C.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 28, 2020
    Applicant: UCL BUSINESS LTD
    Inventors: PAOLO DE COPPI, Luca URBANI, Massimo PINZANI, Guiseppe MAZZA, Claire CROWLEY
  • Patent number: 10654927
    Abstract: The present invention provides a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an antigen binding domain, a transmembrane domain and a first binding domain; and (ii) an intracellular signalling component comprising a signalling domain and a second binding domain which specifically binds the first binding domain of the receptor component; wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain, whereas in the presence of the agent the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 19, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Shaun Cordoba, Khai Kong
  • Patent number: 10632229
    Abstract: The present invention relates generally to methods and materials for use in the production of implants, particularly luminal tissue implants, where the implants are engineered by seeding of an acellular scaffold or matrix with muscle cell precursors and fibroblasts, for example injection seeding using particular ratios of cells. The present invention provides methods for producing tissue engineered constructs for implantation into a subject which can utilise novel seeding processes described herein for improved cell engraftment and differentiation. In addition, the invention describes methods for treating an individual by implantation of the engineered constructs or tissues of the invention.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 28, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Paolo Decoppi, Luca Urbani, Anna Urciuolo